Comparative Pharmacology
Head-to-head clinical analysis: BREVICON 28 DAY versus MIUDELLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREVICON 28 DAY versus MIUDELLA.
BREVICON 28-DAY vs MIUDELLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive; ethinyl estradiol and norethindrone suppress gonadotropin secretion (FSH and LH) via negative feedback, inhibiting ovulation. Additionally, alters cervical mucus consistency and endometrial lining to impede sperm penetration and implantation.
MIUDELLA (everolimus) is an mTOR inhibitor that binds to the FKBP-12 protein to form a complex that inhibits the mTOR kinase activity, thereby reducing cell proliferation, angiogenesis, and glucose uptake.
One tablet (0.5 mg norethindrone and 35 mcg ethinyl estradiol) orally once daily for 28 days (21 active tablets followed by 7 inert tablets).
Intravenous: 1.5 mg/kg every 12 hours for 14 days.
None Documented
None Documented
Norethindrone: 8-11 hours; Ethinyl estradiol: 13-27 hours; half-life for ethinyl estradiol allows once-daily dosing
Terminal elimination half-life is 18-24 hours in healthy adults; prolonged in renal impairment (up to 40 hours in severe cases).
Renal: ~40% as metabolites and unchanged drug; fecal/biliary: ~60% as metabolites
Primarily renal excretion of unchanged drug (85-90%); biliary/fecal elimination accounts for 5-10%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive